Literature DB >> 16443732

cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours.

K Karube1, K Nabeshima, M Ishiguro, M Harada, H Iwasaki.   

Abstract

BACKGROUND: Malignant peripheral nerve sheath tumour (MPNST) is a highly aggressive malignancy that arises within peripheral nerves, and is associated with poor prognosis. Little is known about the underlying biology of MPNST, especially the mechanisms involved in cell proliferation, invasion, or escape from apoptosis. AIMS: To identify genes differentially expressed in MPNST compared with benign tumours, such as neurofibromas and schwannomas, by means of cDNA microarray analysis.
METHODS: Six MPNST cases and five benign cases (three schwannomas and two neurofibromas) were analysed.
RESULTS: Six genes (keratin 18, survivin, tenascin C, adenosine deaminase, collagen type VIa3, and collagen type VIIa1) were significantly upregulated in MPNST, whereas one gene, insulin-like growth factor binding protein 6, was downregulated in MPNST. Survivin and tenascin C expression was validated by reverse transcription polymerase chain reaction. Immunohistochemistry confirmed upregulation of survivin in MPNST at the protein level in six of eight cases compared with benign tumours. Tenascin C was also expressed at the invasive front and tumorous stroma in all MPNST cases. MPNST cells expressed tenascin C in four of nine cases.
CONCLUSIONS: Survivin and tenascin C may be associated with the malignant potential of MPNST and could be considered as potential therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16443732      PMCID: PMC1860323          DOI: 10.1136/jcp.2004.023598

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  36 in total

Review 1.  The Survivin saga goes in vivo.

Authors:  J C Reed
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

2.  The ATM gene in the pathogenesis of mantle-cell lymphoma.

Authors:  S Stilgenbauer; C Schaffner; D Winkler; G Ott; E Leupolt; M Bentz; P Möller; H K Müller-Hermelink; M R James; P Lichter; H Döhner
Journal:  Ann Oncol       Date:  2000       Impact factor: 32.976

Review 3.  Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: biologic and pathologic implications.

Authors:  G K Koukoulis; V E Gould; A Bhattacharyya; J E Gould; A A Howeedy; I Virtanen
Journal:  Hum Pathol       Date:  1991-07       Impact factor: 3.466

4.  Purification from human cerebrospinal fluid of insulin-like growth factor binding proteins (IGFBPs). Isolation of IGFBP-2, an altered form of IGFBP-3 and a new IGFBP species.

Authors:  M Roghani; B Segovia; O Whitechurch; M Binoux
Journal:  Growth Regul       Date:  1991-09

5.  Multi-hormonal regulation of IGFBP-6 expression in human neuroblastoma cells.

Authors:  D Chambery; B De Galle; E Ehrenborg; S Babajko
Journal:  Growth Horm IGF Res       Date:  2000-12       Impact factor: 2.372

Review 6.  The insulin-like growth factors.

Authors:  W S Cohick; D R Clemmons
Journal:  Annu Rev Physiol       Date:  1993       Impact factor: 19.318

7.  The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes.

Authors:  M M Daston; H Scrable; M Nordlund; A K Sturbaum; L M Nissen; N Ratner
Journal:  Neuron       Date:  1992-03       Impact factor: 17.173

Review 8.  Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis.

Authors:  A Grimberg; P Cohen
Journal:  J Cell Physiol       Date:  2000-04       Impact factor: 6.384

9.  Insulin-like growth factor II-mediated proliferation of human neuroblastoma.

Authors:  O M El-Badry; L J Helman; J Chatten; S M Steinberg; A E Evans; M A Israel
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

10.  Pleiotropic cell-division defects and apoptosis induced by interference with survivin function.

Authors:  F Li; E J Ackermann; C F Bennett; A L Rothermel; J Plescia; S Tognin; A Villa; P C Marchisio; D C Altieri
Journal:  Nat Cell Biol       Date:  1999-12       Impact factor: 28.824

View more
  12 in total

Review 1.  Molecular classification of soft tissue sarcomas and its clinical applications.

Authors:  Shilpa Jain; Ruliang Xu; Victor G Prieto; Peng Lee
Journal:  Int J Clin Exp Pathol       Date:  2010-04-23

Review 2.  Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.

Authors:  Matthias Kolberg; Maren Høland; Trude H Agesen; Helge R Brekke; Knut Liestøl; Kirsten S Hall; Fredrik Mertens; Piero Picci; Sigbjørn Smeland; Ragnhild A Lothe
Journal:  Neuro Oncol       Date:  2012-11-15       Impact factor: 12.300

3.  Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors.

Authors:  Markus P Ghadimi; Eric D Young; Roman Belousov; Yiqun Zhang; Gonzalo Lopez; Kristelle Lusby; Christine Kivlin; Elizabeth G Demicco; Chad J Creighton; Alexander J Lazar; Raphael E Pollock; Dina Lev
Journal:  Clin Cancer Res       Date:  2012-03-08       Impact factor: 13.801

4.  DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH.

Authors:  Stine H Kresse; Magne Skårn; Hege O Ohnstad; Heidi M Namløs; Bodil Bjerkehagen; Ola Myklebost; Leonardo A Meza-Zepeda
Journal:  Mol Cancer       Date:  2008-06-03       Impact factor: 27.401

5.  Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors.

Authors:  Su-Jin Park; Birgit Sawitzki; Lan Kluwe; Victor F Mautner; Nikola Holtkamp; Andreas Kurtz
Journal:  BMC Med       Date:  2013-04-23       Impact factor: 8.775

6.  MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression.

Authors:  N Presneau; M Eskandarpour; T Shemais; S Henderson; D Halai; R Tirabosco; A M Flanagan
Journal:  Br J Cancer       Date:  2012-11-22       Impact factor: 7.640

7.  Malignant peripheral nerve sheath tumors: clinicopathological aspects, expression of p53 and survival.

Authors:  Karin S G Cunha; Anabela C Caruso; Paulo A S de Faria; Licínio E da Silva; Andréa R C Pires; Mauro Geller; Vânia S Lopes; Rodrigo S de Moura-Neto
Journal:  Clinics (Sao Paulo)       Date:  2012-08       Impact factor: 2.365

8.  Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.

Authors:  Shyra J Miller; Walter J Jessen; Tapan Mehta; Atira Hardiman; Emily Sites; Sergio Kaiser; Anil G Jegga; Hua Li; Meena Upadhyaya; Marco Giovannini; David Muir; Margaret R Wallace; Eva Lopez; Eduard Serra; G Petur Nielsen; Conxi Lazaro; Anat Stemmer-Rachamimov; Grier Page; Bruce J Aronow; Nancy Ratner
Journal:  EMBO Mol Med       Date:  2009-07       Impact factor: 12.137

9.  Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs.

Authors:  Séverine Tabone-Eglinger; Radislav Bahleda; Jean-François Côté; Philippe Terrier; Dominique Vidaud; Anne Cayre; Alain Beauchet; Nathalie Théou-Anton; Marie-José Terrier-Lacombe; Antoinette Lemoine; Frédérique Penault-Llorca; Axel Le Cesne; Jean-François Emile
Journal:  Sarcoma       Date:  2008

10.  Survivin expression and prognostic significance in pediatric malignant peripheral nerve sheath tumors (MPNST).

Authors:  Rita Alaggio; Riccardo Turrini; Daniela Boldrin; Anna Merlo; Claudio Gambini; Andrea Ferrari; Patrizia Dall'igna; Cheryl M Coffin; Annalisa Martines; Laura Bonaldi; Gian Luca De Salvo; Paola Zanovello; Antonio Rosato
Journal:  PLoS One       Date:  2013-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.